FlowMetric, BurstIQ partner to bring blockchain tech to personalized medicine

Initial applications will focus on FlowMetric's direct-to-consumer line of health and wellness testing products.

Flow cytometry services and personalized medicine testing products provider FlowMetric Life Sciences (Doylestown, PA) has entered into partnership with healthchain blockchain platform developer BurstIQ (Denver, CO).

Related: FlowMetric establishes headquarters at PA Biotechnology Center

Initial applications will focus on FlowMetric's direct-to-consumer line of health and wellness testing products. Coupling this service with the BurstIQ blockchain platform will provide consumers with data security and the ability to govern how their personal information is shared, used, and monetized. FlowMetric's personalized medicine products, which will initially include chromosomal age tests, cellular toxicity analysis, oxidative stress, and inflammation monitoring, will use BurstIQ's digital token-based monetization platform (Token: BIQ) and be offered through BurstIQ's healthcare marketplace.

Future phases of the partnership will bring BurstIQ's blockchain platform and its advanced intelligence layer to FlowMetric's Fortune 500 pharmaceutical customers, enabling secure and auditable chain of custody tracking for clinical sample analysis and secure data exchange between FlowMetric and its enterprise customers.

For more information, please visit www.flowmetric.com and www.burstiq.com.

More in Biophotonics Techniques